A2B 694
Alternative Names: A2B-694Latest Information Update: 16 Feb 2024
At a glance
- Originator A2 Biotherapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 Jan 2024 Phase-I/II clinical trials in Solid tumours (Recurrent, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06051695)
- 28 Sep 2023 A2 Biotherapeutics plans a phase I/II trial for Solid tumors (Recurrent, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) in Q1 2024, (NCT06051695)
- 17 Nov 2021 A2 Biotherapeutics announces intention to submit IND application for Pancreatic cancer, Ovarian cancer, Colorectal cancer, Lung camcer and Mesothelioma (A2 Biotherapeutics pipeline, November 2021)